Novel Therapeutic Targets for Managing Dyslipidemia

Vasanth Sathiyakumar, Karan Kapoor, Steven Jones, Maciej Banach, Seth Martin, Peter P. Toth

Research output: Contribution to journalReview articlepeer-review


Atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of morbidity and mortality in developed nations. Therapeutic modulation of dyslipidemia by inhibiting 3′-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase is standard practice throughout the world. However, based on findings from Mendelian studies and genetic sequencing in prospective longitudinal cohorts from around the world, novel therapeutic targets regulating lipid and lipoprotein metabolism, such as apoprotein C3, angiopoietin-like proteins 3 and 4, and lipoprotein(a), have been identified. These targets may provide additional avenues to prevent and treat atherosclerotic disease. We therefore review these novel molecular targets by addressing available Mendelian and observational data, therapeutic agents in development, and early outcomes results.

Original languageEnglish (US)
Pages (from-to)733-747
Number of pages15
JournalTrends in Pharmacological Sciences
Issue number8
StatePublished - Aug 1 2018


  • angiopoietin-like proteins 3 and 4
  • apoprotein C3
  • ATP citrate lyase
  • lipoprotein(a)
  • lysosomal acid lipase
  • proprotein convertase subtilisin/kexin type 9

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology

Fingerprint Dive into the research topics of 'Novel Therapeutic Targets for Managing Dyslipidemia'. Together they form a unique fingerprint.

Cite this